Thanks.
Definitely all these bits and pieces of new products and services in the Pipeline in CSL R&D programme releases over next 2 to 3 years will have a game changing impact on valuation. Earliest bit of information I am waiting for is the update on merger status and confirmation of the benefits from Vifor acquisition. This should be fairly certain outcome IMO.
News: CSL Csl Behring Receives FDA Approval For Hizentra® (Immune Globulin Subcutaneous <Origin..., page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$263.64 |
Change
8.330(3.26%) |
Mkt cap ! $127.6B | |||
| Open | High | Low | Value | Volume |
| $258.12 | $264.16 | $257.91 | $157.4M | 600.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 119 | $263.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $263.68 | 72 | 12 |
View Market Depth
| Last trade - 13.50pm 22/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |